Fig. 5
Antibacterial activity of DP-AD7anti-acpP against ESBLs-E. coli in the sepsis model. a, b Biodistribtution of DP-AD7anti-acpP in mice determined by in vivo imaging system. Mice were intraperitoneally administrated with 400 μl cy5-labeled DP-AD7. Fluorescent signals were detected in the live mice (a) or the collected organs of the mice (b) 2 h after injection. sp1 and sp2 were two independent samples. c The diagram of treatment and analysis procedure of the in vivo experiment. d Survival rate of BalB/c mice treated with DP-AD7anti-acpP (1.5, 1 and 0.5 mg/kg), DP-AD7mismatch (1.5, 1 or 0.5 mg/kg), or L-DP-ADanti-acpP (1.5 mg/kg) (n = 10). LF2000-NPsanti-acpP (1.5 mg/kg) and ceftazidime (4 mg/kg) were used as positive controls. e, f Colonization of ESBLs-E.coli inocula in liver (e) and kidney (f). Data represent the mean ± SE (n = 6). *p < 0.05